Who we are
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
Navigated Brain Stimulation (NBS) system is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke.
NBS Pre-Surgical Mapping makes the difference to clinical to clinical outcome. Trial has show 46% Increase in Progression-free Survival (Months) in Low Grade Gliomas when using Nexstim NBS together with Direct Cortical Stimulation compared to Direct Cortical Stimulation only.
Nexstim recently filed a 510(k) submission with FDA for NBT® system for the treatment of Major Depressive Disorder (MDD). Nexstim looks forward to introducing the NBT® system for this important indication in early 2018. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.
What we are looking for
We are looking for partners and investors.
Martin Jamieson, Chairman & CEO
Mikko Karvinen, CFO
John Liedtky, VP, Commercialization, General Manager US
Henri Hannula, VP, Sales Europe
Jarmo Laine, VP, Medical Affairs
Gustaf Järnefelt, VP, R&D
Hanna Kotola, VP, Legal Affairs